Stoppel Laura 4
4 · Acumen Pharmaceuticals, Inc. · Filed Jun 7, 2023
Insider Transaction Report
Form 4
Stoppel Laura
Director
Transactions
- Award
Stock Option (right to buy)
2023-06-06+25,000→ 25,000 totalExercise: $5.20Exp: 2033-06-05→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.